Tildrakizumab in the Treatment of Palmoplantar Plaque Psoriasis—A Multicenter Real-World Retrospective Study

IF 1 4区 医学 Q1 DERMATOLOGY
Bárbara Vieira Granja, Júlia Vide, Nuno Preto Gomes, Tiago Torres, Pedro Mendes Bastos, Paulo Morais, Sofia Magina
{"title":"Tildrakizumab in the Treatment of Palmoplantar Plaque Psoriasis—A Multicenter Real-World Retrospective Study","authors":"Bárbara Vieira Granja,&nbsp;Júlia Vide,&nbsp;Nuno Preto Gomes,&nbsp;Tiago Torres,&nbsp;Pedro Mendes Bastos,&nbsp;Paulo Morais,&nbsp;Sofia Magina","doi":"10.1155/dth/9180273","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Introduction</h3>\n \n <p>The palmoplantar region is a high-impact area in psoriasis, with a particularly negative impact on patients’ quality of life. Tildrakizumab has shown efficacy, effectiveness, and safety in the treatment of moderate-to-severe plaque psoriasis but has limited evidence in high-impact areas. The aim of this study was to retrospectively investigate the effectiveness of tildrakizumab in palmoplantar psoriasis.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This was a multicentric, real-world, retrospective study of patients with generalized psoriasis with palmoplantar involvement treated with tildrakizumab 100 mg. Patient data were collected from clinical records, and psoriasis severity was evaluated using the ppPASI, ppPASI &lt; 3, and ppPASI &lt; 1 as co-primary endpoints and the PASI, PGA, BSA, and DLQI as secondary endpoints at baseline and at Weeks 28, 40, and 52 of treatment.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Eighteen patients were included. Mean PASI, BSA, and PGA scores showed a marked reduction from baseline (9.7 ± 6.2; 11.0 ± 7.0; 3.3 ± 0.7) to Week 28 (1.5 ± 1.3; 1.5 ± 1.5; 1.4 ± 1.1), with further improvement at Week 40 (0.9 ± 1.0; 0.9 ± 1.0; 0.9 ± 0.7) and stabilization at Week 52 (1.1 ± 2.2; 1.0 ± 1.6; 0.9 ± 1.1). DLQI scores also improved substantially from baseline (15.1 ± 3.9) to Week 28 (3.7 ± 5.4) and Week 40 (1.4 ± 2.4), with a slight increase between Week 40 and Week 52 (2.3 ± 4.3). Mean ppPASI improved from 15.4 ± 11.1 at baseline to 4.8 ± 12.0 at Week 28 and 1.2 ± 1.6 at Week 40, stabilizing at Week 52 (1.5 ± 2.7). The proportion of patients achieving absolute ppPASI &lt; 3 and ppPASI &lt; 1 increased consistently over time, reaching 61%, 77%, and 81% for ppPASI &lt; 3 and 44%, 62%, and 75% for ppPASI &lt; 1 at Weeks 28, 40, and 52, respectively.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This study, one of the few with 52-week real-world data specifically in palmoplantar psoriasis, confirms that tildrakizumab is a valuable therapeutic option for the treatment of psoriasis in this location, providing effective disease control.</p>\n </section>\n </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9180273","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/dth/9180273","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

The palmoplantar region is a high-impact area in psoriasis, with a particularly negative impact on patients’ quality of life. Tildrakizumab has shown efficacy, effectiveness, and safety in the treatment of moderate-to-severe plaque psoriasis but has limited evidence in high-impact areas. The aim of this study was to retrospectively investigate the effectiveness of tildrakizumab in palmoplantar psoriasis.

Methods

This was a multicentric, real-world, retrospective study of patients with generalized psoriasis with palmoplantar involvement treated with tildrakizumab 100 mg. Patient data were collected from clinical records, and psoriasis severity was evaluated using the ppPASI, ppPASI < 3, and ppPASI < 1 as co-primary endpoints and the PASI, PGA, BSA, and DLQI as secondary endpoints at baseline and at Weeks 28, 40, and 52 of treatment.

Results

Eighteen patients were included. Mean PASI, BSA, and PGA scores showed a marked reduction from baseline (9.7 ± 6.2; 11.0 ± 7.0; 3.3 ± 0.7) to Week 28 (1.5 ± 1.3; 1.5 ± 1.5; 1.4 ± 1.1), with further improvement at Week 40 (0.9 ± 1.0; 0.9 ± 1.0; 0.9 ± 0.7) and stabilization at Week 52 (1.1 ± 2.2; 1.0 ± 1.6; 0.9 ± 1.1). DLQI scores also improved substantially from baseline (15.1 ± 3.9) to Week 28 (3.7 ± 5.4) and Week 40 (1.4 ± 2.4), with a slight increase between Week 40 and Week 52 (2.3 ± 4.3). Mean ppPASI improved from 15.4 ± 11.1 at baseline to 4.8 ± 12.0 at Week 28 and 1.2 ± 1.6 at Week 40, stabilizing at Week 52 (1.5 ± 2.7). The proportion of patients achieving absolute ppPASI < 3 and ppPASI < 1 increased consistently over time, reaching 61%, 77%, and 81% for ppPASI < 3 and 44%, 62%, and 75% for ppPASI < 1 at Weeks 28, 40, and 52, respectively.

Conclusion

This study, one of the few with 52-week real-world data specifically in palmoplantar psoriasis, confirms that tildrakizumab is a valuable therapeutic option for the treatment of psoriasis in this location, providing effective disease control.

Abstract Image

Tildrakizumab治疗掌跖斑块银屑病-多中心真实世界回顾性研究
掌跖区是银屑病的高影响区,对患者生活质量的影响尤为负面。Tildrakizumab在治疗中度至重度斑块性银屑病方面已显示出疗效、有效性和安全性,但在高影响领域的证据有限。本研究的目的是回顾性研究tildrakizumab治疗掌足底银屑病的有效性。方法:这是一项多中心、真实世界的回顾性研究,研究对象是接受tildrakizumab 100mg治疗的广泛性银屑病伴掌跖受累患者。从临床记录中收集患者数据,在基线和治疗第28、40和52周时,以ppPASI、ppPASI <; 3和ppPASI <; 1作为共同主要终点,PASI、PGA、BSA和DLQI作为次要终点,对银屑病严重程度进行评估。结果共纳入18例患者。平均PASI、BSA和PGA评分从基线(9.7±6.2;11.0±7.0;3.3±0.7)到第28周(1.5±1.3;1.5±1.5;1.4±1.1)显著降低,第40周进一步改善(0.9±1.0;0.9±1.0;0.9±0.7),第52周稳定(1.1±2.2;1.0±1.6;0.9±1.1)。DLQI评分也从基线(15.1±3.9)到第28周(3.7±5.4)和第40周(1.4±2.4)显著改善,在第40周和第52周之间略有增加(2.3±4.3)。平均ppPASI从基线的15.4±11.1改善到第28周的4.8±12.0和第40周的1.2±1.6,在第52周稳定(1.5±2.7)。随着时间的推移,达到绝对ppPASI <; 3和ppPASI <; 1的患者比例持续增加,在第28、40和52周分别达到61%、77%和81%的ppPASI <; 3和44%、62%和75%的ppPASI <; 1。该研究是为数不多的针对掌跖牛皮癣的52周真实数据之一,证实tildrakizumab是治疗该部位牛皮癣的有价值的治疗选择,提供有效的疾病控制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Dermatologic Therapy
Dermatologic Therapy 医学-皮肤病学
CiteScore
7.00
自引率
8.30%
发文量
711
审稿时长
3 months
期刊介绍: Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书